SCHEMBL19956891

SCHEMBL19956891

CNc1c(Nc2cccnc2)c(=O)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
RAD52 P43351 1/20 0.49
TDP2 O95551 1/20 0.44
NSD2 O96028 1/20 0.44
TDO2 P48775 1/20 0.43
ADRA2A P08913 2/20 0.41
ADRA2B P18089 2/20 0.41
ADRA2C P18825 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 2/20 0.41
BUB1 O43683 1/20 0.41
KIF11 P52732 1/20 0.41
MAPKAPK2 P49137 2/20 0.40
ROCK1 Q13464 2/20 0.40
AURKB Q96GD4 2/20 0.40
DCLK1 O15075 1/20 0.40
ROCK2 O75116 1/20 0.40
CHEK2 O96017 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7349452 0.82 PLK1 (0.55) KMT2ARAD52TDP2NSD2NPC1
SCHEMBL7350556 0.80 MAPKAPK2 (0.43) KMT2ARAD52TDP2NSD2NPC1
SCHEMBL7346763 0.79 TDO2 (0.50) KMT2ARAD52TDP2NSD2TDO2
SCHEMBL2771874 0.79 POLB (0.46) KMT2ARAD52TDP2NSD2RAB9A
SCHEMBL7351783 0.79 RAD52 (0.45) KMT2ARAD52TDP2NSD2TDO2
SCHEMBL6987237 0.79 KMT2A (0.42) KMT2ARAD52TDP2NSD2TDO2
SCHEMBL24872319 0.78 ROCK1 (0.58) MAPK1MAPKAPK2ROCK1AURKBDCLK1
SCHEMBL19956913 0.77 CXCR2 (0.56) KMT2AMAPK1MAPKAPK2ROCK1AURKB
SCHEMBL8371986 0.77 PLK1 (0.70) MAPK1MAPKAPK2ROCK1AURKBDCLK1
SCHEMBL7345066 0.77 PLK1 (0.70) MAPK1MAPKAPK2ROCK1AURKBDCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 KMT2A 1030/4885RAD52 4792/4885TDP2 1301/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 KMT2A 1030/4885RAD52 4792/4885TDP2 1301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.